tralokinumab is an approved drug (EMA & FDA (2021))
Compound class:
Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Atopic dermatitis |
Disease Ontology:
DOID:3310 OMIM: 603165 |
Phase 3 clinical candidate for atopic dermatitis (see NCT03131648). | |
| Alopecia areata |
Disease Ontology:
DOID:986 |
Phase 2 clinical candidate for alopecia areata (see NCT02684097). | |
| Asthma |
Disease Ontology:
DOID:2841 OMIM: 600807 |
Phase 3 clinical candidate for uncontrolled asthma (see NCT02161757). | |
